Antihyperglycemics (DPP-4 inhibitors)
- Modest oral glucose-lowering drugs
- Weight-neutral; very low hypoglycemia
- Sitagliptin/linagliptin common
- Linagliptin needs no renal dose adjustment
- Less potent than GLP-1/SGLT2 therapies
- Saxagliptin: HF hospitalization concern
- Do not routinely combine with GLP-1 drugs
Class at a glance
- Modest oral glucose-lowering drugs
Members / distinctions
- Less potent than GLP-1/SGLT2 therapies
- Saxagliptin: HF hospitalization concern
Practical pearls
- Sitagliptin/linagliptin common
- Do not routinely combine with GLP-1 drugs
Other member distinctions
- Weight-neutral; very low hypoglycemia
- Linagliptin needs no renal dose adjustment
Self-check
- Should Antihyperglycemics (DPP-4 inhibitors) routinely be combined with GLP-1 drugs?
No. - Which DPP-4 inhibitor needs no renal dose adjustment?
Linagliptin.
Drugs in this class (4)
Antihyperglycemics (DPP-4 inhibitors) prescription history
Animated chart of estimated U.S. prescriptions per year, Diabetes meds (1923–2026). DPP-4 inhibitor highlighted from 2006.
All drug classes · Open Antihyperglycemics (DPP-4 inhibitors) in the interactive console ↗